SCHEMBL2777919

SCHEMBL2777919

CCOC(=O)c1ncc2c(-c3cccs3)noc2c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
TSHR P16473 1/20 0.45
ALDH1A1 P00352 6/20 0.44
HPGD P15428 6/20 0.44
KDM4E B2RXH2 5/20 0.44
GAA P10253 3/20 0.44
CASP1 P29466 1/20 0.44
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 4/20 0.41
PKM P14618 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KEAP1 Q14145 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39
FOS P01100 1/20 0.38
JUN P05412 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2776420 0.82 ALDH1A1 (0.46) MAPTTSHRALDH1A1HPGDKDM4E
SCHEMBL2775027 0.81 CDC7 (0.44) ALDH1A1HPGDCASP1NPSR1HSD17B10
SCHEMBL2777247 0.80 ALDH1A1 (0.48) MAPTTSHRALDH1A1HPGDKDM4E
SCHEMBL2776306 0.78 ALDH1A1 (0.43) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL3660246 0.78 MEN1 (0.35) MAPTTSHRALDH1A1KMT2ATP53
SCHEMBL2775883 0.78 EGLN1 (0.53) KMT2ANPSR1SMN1; SMN2
SCHEMBL2776184 0.77 TARBP2 (0.48) MAPTALDH1A1GAAKMT2APOLB
SCHEMBL2776412 0.77 ALDH1A1 (0.45) MAPTTSHRALDH1A1HPGDKDM4E
SCHEMBL2778422 0.77 ALDH1A1 (0.49) MAPTALDH1A1HPGDKDM4EKMT2A
SCHEMBL2779072 0.76 KDM4E (0.44) MAPTTSHRALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 MAPT 3874/4885TSHR 3158/4885ALDH1A1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.